Aerify3: A Potential New Treatment for Airway Inflammation in COPD
Trial Objectives
Treatments for chronic obstructive pulmonary disease (COPD) may still leave people experiencing wheezing, coughing, or shortness of breath. Researchers in the Aerify3 study are investigating a medication called itepekimab, which has shown some potential in earlier clinical trials to improve symptoms in those with COPD.
COPD symptoms can be worsened by inflammation in the lungs that makes it harder to breathe. Itepekimab has been shown to reduce inflammation in the body without suppressing the immune system. This trial is investigating changes in gene expression in those treated with this drug to evaluate how their lung inflammation has been reduced.
Participants will undergo two bronchoscopies within the first 12 weeks of the study, and biopsies will be taken to study gene expression during the procedures. They also will be monitored for changes of symptoms and receive blood tests to monitor
changes in the blood cells.
Who Can Participate
People with a diagnosis of pulmonary sarcoidosis, who are receiving oral prednisone treatment and have been on a clinically stable dose of oral corticosteroid for at least 4 weeks.
Age: 40-70 Gender: Any
Estimated Time Commitment
Approximately 9 clinic visits and 1 telephone visit, once every two weeks. Visits will take 1-4 hours
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Jennifer Underwood
303.398.1518
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Sanofi